No Prescription |
 |
 | ||
|
Vergo Generic Betahistine |
|
| ||
No Prescription » Prescription Drugs 17 » Vergo Generic Betahistine IndicationsMeniere's Syndrome as defined by the following core symptoms:vertigo (with nausea/vomiting) hearing loss (hardness of hearing) tinnitus Dosage and AdministrationThe usual adult initial dose is 8 mg three to four times daily later reduced to 8 to 16 mg daily for maintenance depending on patient response. The maximum recommended daily dosage is 32 mg.The dosage should be individually adapted according to the response. Improvement can sometimes only be observed after a couple of weeks of treatment. Buy Vergo Generic Betahistine and other Prescription Drugs 17 products online at Medstore. Buy Online at Medstore - Click Here!
About Vergo Generic Betahistine: Product Type: Prescription Drugs 17 Vergo ( Generic Betahistine ) Vergo (Generic Betahistine) Generic Betahistine 16mg Generic Betahistine Vergo
View more Prescription Drugs 17 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
